DE69931789D1 - Behandlung von nicotinsucht und sucht bedingtem verhalten - Google Patents

Behandlung von nicotinsucht und sucht bedingtem verhalten

Info

Publication number
DE69931789D1
DE69931789D1 DE69931789T DE69931789T DE69931789D1 DE 69931789 D1 DE69931789 D1 DE 69931789D1 DE 69931789 T DE69931789 T DE 69931789T DE 69931789 T DE69931789 T DE 69931789T DE 69931789 D1 DE69931789 D1 DE 69931789D1
Authority
DE
Germany
Prior art keywords
treatment
nicotine
seek
assessment
conditional behavior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931789T
Other languages
English (en)
Other versions
DE69931789T2 (de
Inventor
L Dewey
D Brodie
R Ashby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Brookhaven Science Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/129,253 external-priority patent/US6057368A/en
Application filed by Brookhaven Science Associates LLC filed Critical Brookhaven Science Associates LLC
Application granted granted Critical
Publication of DE69931789D1 publication Critical patent/DE69931789D1/de
Publication of DE69931789T2 publication Critical patent/DE69931789T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
DE69931789T 1998-08-05 1999-08-05 Behandlung von nicotinsucht und sucht bedingtem verhalten Expired - Lifetime DE69931789T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US189166 1980-09-22
US129253 1993-09-29
US09/129,253 US6057368A (en) 1998-08-05 1998-08-05 Treatment of addiction and addiction-related behavior
US09/189,166 US6828349B1 (en) 1998-08-05 1998-11-09 Treatment of addiction and addiction-related behavior
US209952 1998-12-11
US09/209,952 US6541520B1 (en) 1998-08-05 1998-12-11 Treatment of addiction and addiction-related behavior
PCT/US1999/017220 WO2000007583A2 (en) 1998-08-05 1999-08-05 Treatment of addiction and addiction-related behavior

Publications (2)

Publication Number Publication Date
DE69931789D1 true DE69931789D1 (de) 2006-07-20
DE69931789T2 DE69931789T2 (de) 2007-05-24

Family

ID=27383860

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931789T Expired - Lifetime DE69931789T2 (de) 1998-08-05 1999-08-05 Behandlung von nicotinsucht und sucht bedingtem verhalten

Country Status (24)

Country Link
US (4) US6541520B1 (de)
EP (1) EP1102583B1 (de)
JP (1) JP2002522383A (de)
CN (1) CN1172663C (de)
AT (1) ATE328588T1 (de)
AU (1) AU772715B2 (de)
BR (1) BR9912760A (de)
CA (1) CA2339192C (de)
CY (1) CY1105214T1 (de)
CZ (1) CZ2001394A3 (de)
DE (1) DE69931789T2 (de)
DK (1) DK1102583T3 (de)
ES (1) ES2267287T3 (de)
HR (1) HRP20010085A2 (de)
HU (1) HUP0103377A3 (de)
ID (1) ID28916A (de)
IL (1) IL141067A0 (de)
MX (1) MXPA01001268A (de)
NO (1) NO20010539L (de)
NZ (1) NZ509682A (de)
PL (1) PL198789B1 (de)
PT (1) PT1102583E (de)
TW (1) TWI243674B (de)
WO (1) WO2000007583A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
CA2341400A1 (en) * 1998-08-25 2000-03-02 Sepracor, Inc. Methods and compositions employing optically pure s(+) vigabatrin
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
CN100548290C (zh) * 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
WO2000066108A2 (en) * 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency
IT1313585B1 (it) * 1999-07-30 2002-09-09 Neuroscienze S C A R L Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
US6395783B1 (en) * 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
US6462084B1 (en) * 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US7041650B2 (en) 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7822470B2 (en) * 2001-10-11 2010-10-26 Osypka Medical Gmbh Method for determining the left-ventricular ejection time TLVE of a heart of a subject
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1494998A2 (de) * 2002-03-01 2005-01-12 University Of South Florida Mehrkomponenten festphasen enthaltend wenigstens einen pharmazeutischen wirkstoff
US6797707B2 (en) * 2002-03-29 2004-09-28 University Of Florida Antagonists of RF-amide neuropeptides
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
PE20070043A1 (es) * 2005-05-17 2007-02-05 Wm Internat Ltd Aparato y metodo para la estabilizacion no quimica de bio-solidos
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
AU2006287378A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US8889194B2 (en) * 2006-06-21 2014-11-18 Harlan Clayton Bieley Smoking cessation with body weight maintenance and nutritional supplement
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
PL2061458T3 (pl) * 2006-09-15 2015-07-31 Univ Minnesota Kompozycje topiramatu i sposoby ich stosowania
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
CN101636159A (zh) * 2007-01-23 2010-01-27 公立大学法人名古屋市立大学 用于预防和治疗阿尔茨海默型痴呆症的药物
CN106983747A (zh) 2007-08-06 2017-07-28 生物系治疗公司 治疗依赖性的方法
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2775890C (en) * 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20120046232A1 (en) * 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
US20140072935A1 (en) * 2012-09-07 2014-03-13 Tina M. Herron Method of Regulating Caloric Intake
EP3446685A1 (de) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3122336A4 (de) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Missbrauchssichere biphasische feste darreichungsform mit unmittelbarer freisetzung
EP3151906B1 (de) 2014-06-03 2019-12-11 Pop Test Abuse Deterrent Technology LLC Zur drahtlosen kommunikation konfigurierte arzneimittelvorrichtung
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN114903006A (zh) * 2021-02-09 2022-08-16 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物物质成瘾模型的构建方法与应用
US20220354822A1 (en) * 2021-05-05 2022-11-10 Mind Medicine, Inc. Mdma enantiomers
CN115386421A (zh) * 2022-06-23 2022-11-25 江苏华熙益能生物科技有限公司 烟叶用香精、制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639607A (en) 1970-11-02 1972-02-01 Jack E Phillips Method for treating the tobacco smoking habit
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
NZ194348A (en) * 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
GB2133002B (en) 1982-12-30 1986-01-29 Merrell Toraude & Co Process for preparing 4-amino-5-hexenoic acid
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
JPH03500411A (ja) 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
EP0509180A1 (de) * 1991-04-18 1992-10-21 Merrell Dow Pharmaceuticals Inc. Verwendung von GABA-T-Inhibitoren zur Behandlung der Schizophrenie und der Phencyclidinvergiftung
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
US5332736A (en) * 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
KR20010031470A (ko) 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
MXPA01004015A (es) 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
CN100548290C (zh) 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
WO2000066108A2 (en) 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency

Also Published As

Publication number Publication date
NO20010539D0 (no) 2001-01-31
WO2000007583A2 (en) 2000-02-17
PL198789B1 (pl) 2008-07-31
CN1172663C (zh) 2004-10-27
IL141067A0 (en) 2002-02-10
NO20010539L (no) 2001-04-02
WO2000007583A3 (en) 2000-09-08
US6541520B1 (en) 2003-04-01
CZ2001394A3 (cs) 2001-08-15
DE69931789T2 (de) 2007-05-24
ATE328588T1 (de) 2006-06-15
HUP0103377A3 (en) 2003-11-28
CA2339192C (en) 2009-12-22
US6593367B1 (en) 2003-07-15
PT1102583E (pt) 2006-10-31
DK1102583T3 (da) 2006-10-09
EP1102583B1 (de) 2006-06-07
AU772715B2 (en) 2004-05-06
US6323239B1 (en) 2001-11-27
HRP20010085A2 (en) 2002-02-28
ES2267287T3 (es) 2007-03-01
TWI243674B (en) 2005-11-21
JP2002522383A (ja) 2002-07-23
US6906099B2 (en) 2005-06-14
BR9912760A (pt) 2001-10-09
US20020037925A1 (en) 2002-03-28
EP1102583A2 (de) 2001-05-30
HUP0103377A2 (hu) 2002-01-28
AU5545299A (en) 2000-02-28
CA2339192A1 (en) 2000-02-17
MXPA01001268A (es) 2003-07-14
PL347912A1 (en) 2002-04-22
CY1105214T1 (el) 2010-03-03
NZ509682A (en) 2004-01-30
ID28916A (id) 2001-07-12
CN1326342A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
DE69931789D1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
ATE410157T1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
DE69626660T2 (de) 2-alkylpyrrolidine
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
DE69619506D1 (de) Nonpeptid tachykinin antagoniste
FI963294A (fi) Naftyyliamidit keskushermostoaineina
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
ATE240115T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE249835T1 (de) Immunoregulator
DE60025639D1 (de) Substituierte diazepan
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
DE69813022D1 (de) Injektor zur behandlung von metallschmelzen mit gasen
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
MXPA02012894A (es) Catecoles nitrados substituidos, su uso en el tratamiento de algunos trastornos del sistema nervioso central y periferico y composiciones farmaceuticas que los contienen.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
DE60222552D1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen
Thompson Toward Baptist ecclesiology in pneumatological perspective
TR200101476T2 (tr) N-ikameli azabisikloaklan türevlerinin merkezi sinir sistemi bozukluklarının tedavisinde kullanılması

Legal Events

Date Code Title Description
8364 No opposition during term of opposition